Page 23 - IMO-2-2

Innovative Medicines & Omics Pharmacotherapy of obesity

44. Costa-Font J, Mas N. “Globesity”? The effects of globalization obesity drug. Eur J Pharmacol. 2002;440(2-3):109-117.
on obesity and caloric intake. Food Policy. 2016;64:121-132.
doi: 10.1016/S0014-2999(02)01422-X
doi: 10.1016/J.FOODPOL.2016.10.001
57. García Díaz E, Martín Folgueras T. Systematic review of the
45. Ruban A, Stoenchev K, Ashrafian H, Teare J. Current clinical efficacy of sibutramine and orlistatin weigth loss,
treatments for obesity. Clin Med. 2019;19(3):205-212. quality of life and its adverse effects in obese adolescents.
Nutr Hosp. 2011;26(3):451-457.
doi: 10.7861/CLINMEDICINE.19-3-205
doi: 10.3305/nh.2011.26.3.5123
46. Astrup A, Raben A, Geiker N. The role of higher protein
diets in weight control and obesity-related comorbidities. Int 58. Topaloglu O, Sahin I. Pharmacological treatment of obesity
J Obes. 2015;39:721-726. in clinical practice. Med Sci Int Med J. 2021;10(2):651.
doi: 10.1038/ijo.2014.216 doi: 10.5455/medscience.2021.05.151
47. Dalle Grave R, Sartirana M, Calugi S. Personalized cognitive- 59. Alruwaili H, Dehestani B, Le Roux CW. Clinical impact
behavioural therapy for obesity (CBT-OB): Theory, strategies of liraglutide as a treatment of obesity. Clin Pharmacol.
and procedures. Biopsychosoc Med. 2020;14(1):5. 2021;13:53-60.
doi: 10.1186/s13030-020-00177-9 doi: 10.2147/CPAA.S276085
48. Chaput JP, Tremblay A. Adequate sleep to improve the 60. Xie Z, Yang S, Deng W, Li J, Chen J. Efficacy and safety of
treatment of obesity. CMAJ. 2012;184(18):1975-1976. liraglutide and semaglutide on weight loss in people with
obesity or overweight: A systematic review. Clin Epidemiol.
doi: 10.1503/cmaj.120876
2022;14:1463-1476.
49. Wadden TA, Foster GD. Behavioral treatment of obesity.
Med Clin North Am. 2000;84(2):441-461. doi: 10.2147/CLEP.S391819
61. Mehta A, Marso SP, Neeland IJ. Liraglutide for weight
doi: 10.1016/S0025-7125(05)70230-3
management: A critical review of the evidence. Obes Sci
50. Elder KA, Wolfe BM. Bariatric surgery: A review of procedures Pract. 2017;3(1):3-14.
and outcomes. Gastroenterology. 2007;132(6):2253-2271.
doi: 10.1002/osp4.84
doi: 10.1053/j.gastro.2007.03.057
62. Kelly AS, Auerbach P, Barrientos-Perez M, et al.
51. Byrne TK. Complications of surgery for obesity. Surg Clin A randomized, controlled trial of liraglutide for adolescents
North Am. 2001;81(5):1181-1193. with obesity. N Engl J Med. 2020;382(22):2117-2128.
doi: 10.1016/S0039-6109(05)70190-0 doi: 10.1056/nejmoa1916038
52. Chakhtoura M, Haber R, Ghezzawi M, Rhayem C, Tcheroyan 63. Garnett WR. Clinical pharmacology of topiramate: A review.
R, Mantzoros CS. Pharmacotherapy of obesity: An update Epilepsia. 2000;41:61-65.
on the available medications and drugs under investigation. doi: 10.1111/j.1528-1157.2000.tb02174.x
EClinicalMedicine. 2023;58:101882.
64. Cosentino G, Conrad AO, Uwaifo GI. Phentermine and
doi: 10.1016/j.eclinm.2023.101882
topiramate for the management of obesity: A review. Drug
53. Wang D, Benito PJ, Rubio-Arias JA, Ramos-Campo DJ, Des Devel Ther. 2013;7:267-278.
Rojo-Tirado MA. Exploring factors of adherence to weight doi: 10.2147/DDDT.S31443
loss interventions in population with overweight/obesity:
An umbrella review. Obes Rev. 2024;25:e13783. 65. Smith SM, Meyer M, Trinkley KE. Fentermina/topiramato
(qsymia) para el tratamiento de obesidad. Ann Pharmacother.
doi: 10.1111/obr.13783
2013;47(3):340-349.
54. Hao X, Zhu X, Tian H, et al. Pharmacological effect and doi: 10.1345/aph.1R501
mechanism of orlistat in anti-tumor therapy: A review.
Medicine (Baltimore). 2023;102(36):E34671. 66. Liu Y, Han F, Xia Z, et al. The effects of bupropion alone
and combined with naltrexone on weight loss: A systematic
doi: 10.1097/MD.0000000000034671
review and meta-regression analysis of randomized
55. Nikniaz Z, Nikniaz L, Farhangi MA, Mehralizadeh H, controlled trials. Diabetol Metab Syndr. 2024;16(1):93.
Salekzamani S. Effect of Orlistat on anthropometrics and doi: 10.1186/s13098-024-01319-7
metabolic indices in children and adolescents: A systematic
review and meta-analysis. BMC Endocr Disord. 2023;23:142. 67. Le Roux CW, Fils-Aimé N, Camacho F, Gould E, Barakat M.
The relationship between early weight loss and weight
doi: 10.1186/s12902-023-01390-7
loss maintenance with naltrexone-bupropion therapy.
56. Ballinger A, Peikin SR. Orlistat: Its current status as an anti- EClinicalMedicine. 2022;49:101436.

Volume 2 Issue 2 (2025) 17 doi: 10.36922/imo.8316